Autoimmune Cell Therapy 2 articles

Autoimmune Cell Therapy examines engineered or intensive cell-based strategies designed to reset pathogenic immune activity in autoimmune disease. CAR-T approaches, B-cell depletion, immune repertoire remodeling, durability, safety and patient selection are relevant when the goal is immune reconstitution rather than cancer treatment. The category is intentionally separated from oncology-focused CAR-T coverage because disease biology, acceptable toxicity, treatment goals and evidence standards can differ substantially in autoimmune settings.

Clinical Trials & Evidence

October 2, 2026, 8:53 AM · 4 mins read

CRISPR Therapeutics reveals first human data for gene-edited CAR T therapy in systemic sclerosis

CRISPR Therapeutics will share initial clinical results for its allogeneic CRISPR/Cas9-edited CAR T cell therapy zugocabtagene geleucel, targeting CD19 in hard-to-treat systemic sclerosis, at ACR Convergence 2026.

Clinical Trials & Evidence

October 2, 2026, 5:56 AM · 5 mins read

Rheumatologist trust in CAR T therapies drops after safety scares, but autologous approach still leads

Recent deaths and severe side effects in CAR T trials have rattled rheumatologists. Despite the drop in confidence, autologous CAR T remains the top pick, even as new hurdles emerge.